Enliven Therapeutics Inc.
$ 40.36
9.08%
11 Jun - close price
- Market Cap 2,458,124,000 USD
- Current Price $ 40.36
- High / Low $ 45.52 / 40.24
- Stock P/E N/A
- Book Value 7.45
- EPS -1.64
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.27 %
- 52 Week High 48.53
- 52 Week Low 14.79
About
Enliven Therapeutics Inc. (Ticker: ELVN) is an innovative biotechnology company focused on transforming cancer treatment and addressing critical health challenges through its proprietary therapeutic platforms. The company is advancing a diverse portfolio of drug candidates, leveraging cutting-edge biopharmaceutical technologies to enhance patient outcomes and elevate quality of life. With a steadfast commitment to scientific excellence and a strategic focus on fulfilling unmet medical needs in oncology, Enliven Therapeutics is poised to generate substantial shareholder value while making significant impacts within the healthcare sector.
Analyst Target Price
$60.11
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-03 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-03-13 | 2024-11-13 | 2024-08-13 | 2024-05-14 | 2024-03-14 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.38 | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 |
| Estimated EPS | -0.41 | -0.3778 | -0.46 | -0.42 | -0.5 | -0.5175 | -0.5 | -0.56 | -0.57 | -0.54 | -0.47 | -0.4 |
| Surprise | 0.03 | -0.1022 | 0.14 | -0.07 | -0.07 | 0.0575 | 0.02 | 0.15 | 0.03 | 0.07 | -0.04 | -0.01 |
| Surprise Percentage | 7.3171% | -27.0513% | 30.4348% | -16.6667% | -14% | 11.1111% | 4% | 26.7857% | 5.2632% | 12.963% | -8.5106% | -2.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.4 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELVN
2026-06-12 14:38:46
Enliven Therapeutics has priced an upsized public offering, raising $400 million through the sale of common stock and pre-funded warrants. This financial move aims to secure capital for the company's operations and potentially advance its therapeutic pipeline. The offering reflects investor interest in Enliven Therapeutics' future prospects.
2026-06-12 02:50:13
Enliven Therapeutics Inc. has priced an underwritten public offering of 8,933,334 shares of common stock at $37.50 per share, with gross proceeds expected to be approximately $400 million. The biopharmaceutical company also offered pre-funded warrants. The offering is anticipated to close around June 15, 2026, and the company's stock has seen a significant year-to-date gain, though InvestingPro analysis suggests it may be overvalued.
2026-06-12 02:43:13
Enliven Therapeutics has priced an upsized public offering of 8,933,334 common shares at $37.50 each and pre-funded warrants for up to 1,733,333 shares at $37.499, aiming to raise approximately $400 million in gross proceeds. The offering is expected to close around June 15, 2026, and includes a 30-day option for underwriters to purchase an additional 1,600,000 shares. This financing continues Enliven's strategy to fund the development of ELVN-001 and support broader growth plans.
2026-06-12 02:39:13
Enliven Therapeutics has priced an upsized underwritten public offering of 8,933,334 shares of its common stock at $37.50 per share, and pre-funded warrants for 1,733,333 shares at $37.499 per warrant, aiming to raise approximately $400.0 million. The offering is expected to close around June 15, 2026. Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley, and Barclays are among the joint book-running managers.
2026-06-11 20:03:00
Enliven Therapeutics Inc. (ELVN) stock has risen over 12% following positive clinical trial progress for its CML therapy candidate, ELVN-001. Wall Street analysts have initiated or raised coverage with bullish price targets, citing ELVN-001's potential as a best-in-class treatment and the company's strong financial position for upcoming Phase 3 trials. The stock is attracting traders due to strong catalysts including upcoming data presentations, aggressive analyst support, and technical momentum despite being pre-revenue.
2026-06-11 19:38:46
Enliven Therapeutics announced a proposed under
